NHS Framework Agreement for Branded Medicines - Tranche B - NOFE & MAE and Eculizumab & Ravulizumab for London & SOFE - 01 September 2025
Awarded by NHS England · 2025-02-17T10:24:38Z · £2,028,332,000
Description
NHS Framework Agreement for Branded Medicines - Tranche B - NOFE & MAE and Eculizumab & Ravulizumab for London & SOFE - 01 September 2025 Offer reference number: CM/PHR/24/5680 CM/PHR/24/5680/01 - NHS Framework Agreement for Branded Medicines - Tranche B for North of England and Midlands & East. Period of Framework Agreement: 01 September 2025 to 31 August 2027 CM/PHR/24/5680/02 - NHS Framework Agreement for Branded Medicines - Eculizumab and Ravulizumab for London & SOFE. …
- Buyer
- NHS England
- Value
- £2,028,332,000
- Category (CPV)
- Pharmaceutical products
- Award date
- 2025-02-17T10:24:38Z
- Buyer constituency
- runcorn-and-helsby
Full CPV hierarchy, related awards from the same supplier and buyer, and any declared MP interest overlaps load below when JavaScript is enabled.